



RE
D
PATENT
TECH CENTER 1600/2900
ATTORNEY DOCKET NO.: 28911/35930

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:) I hereby certify that this paper and the
) documents referred to as enclosed herewith
Greg Firth) are being deposited with the United States
) Postal Service as First Class Mail, postage
) prepaid, in an envelope addressed to:
Serial No.: 09/380,932 filed September) Commissioner for Patents, Washington, D.C.
10, 1999, U.S. National Phase)
Application Based on PCT/GB98/00840)
filed March 20, 1998 Based on EP)
97301917.7 filed March 21, 1997)
)
) December 6, 2000
For: Extraction and Utilisation of VNTR)
Alleles)
)
Group Art Unit: 1635) Jeffrey S. Sharp
) Reg. No.: 31,879
Examiner: M. Shibuya, Ph.D.) Attorney for Applicant

#10/Seq.
Listing

STATEMENT UNDER 37 C.F.R. §§1.821(f)

Commissioner for Patents
Washington, DC 20231

Sir:

I hereby state that the content of the paper and computer readable copies of the Sequence Listing, submitted herewith in accordance with 37 C.F.R. §§1.821 and 1.825, are the same.

Respectfully submitted,

MARSHALL, O'TOOLE, GERSTEIN,
MURRAY & BORUN
6300 Sears Tower
233 South Wacker Drive
Chicago, Illinois 60606-6402
(312) 474-6300

By:

Jeffrey S. Sharp
Reg. No. 31,879
Attorney for Applicants

December 6, 2000



- 1 -

SEQUENCE LISTING

<110> FIRTH, Greg

<120> EXTRACTION AND UTILISATION OF VNTR ALLELES

<130> 28911/35930

<140> 09/380,932

<141> 2000-01-18

<150> PCT/GB98/00840

<151> 1998-03-20

<150> EP 97301917.7

<151> 1997-03-21

<160> 10

<170> PatentIn Ver. 2.0

<210> 1

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: sense primer

<400> 1
atgcctgcag gtcgactcta gagga 25

<210> 2

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: antisense primer

<220>

<223> the antisense primer is identified in the specification in the 3' to 5' position; the antisense primer is identified in the sequence listing in the 5' to 3' position.

<400> 2
ctcactatag ggaattcgag ctcgg 25

<210> 3

<211> 71

<212> DNA

<213> genomic DNA

<400> 3
gccaagcttg catgcctgca ggctgactct agaggatccc cgggtaccga gctcgaattc 60
cctatagtga g 71

<210> 4

<211> 24

<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
oligonucleotide

<400> 4
gcaggagaca tcgaaggtat gaac 24

<210> 5
<211> 12
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
oligonucleotide

<400> 5
ttcatacctt cg 12

<210> 6
<211> 16
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
oligonucleotide

B"
<400> 6
gatcgttcat accttc 16

<210> 7
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: sense primer

<400> 7
cacttgggac tttggattgg tca 23

<210> 8
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: antisense
primer

<400> 8
gtcttttgttt ccattcttgc ttgc 24

<210> 9
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
oligonucleotide

<400> 9
ctcgcaagga tgggatgctc g

21

<210> 10
<211> 12
<212> DNA
<213> Artificial Sequence

B¹¹
<220>
<223> Description of Artificial Sequence:
oligonucleotide

<400> 10
catccttgcg ag

12
